<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="Minion" color="#231f20"/>
	<fontspec id="1" size="10" family="Minion" color="#000000"/>
	<fontspec id="2" size="10" family="MinionExp" color="#231f20"/>
	<fontspec id="3" size="12" family="Minion-Black" color="#231f20"/>
	<fontspec id="4" size="10" family="Minion" color="#231f20"/>
	<fontspec id="5" size="7" family="Minion" color="#231f20"/>
	<fontspec id="6" size="9" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="7" size="6" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="8" size="9" family="PATextEx" color="#231f20"/>
	<fontspec id="9" size="10" family="MinionProMath" color="#231f20"/>
<text top="45" left="51" width="5" height="9" font="0">2</text>
<text top="45" left="373" width="176" height="9" font="0">International Journal of Alzheimer’s Disease</text>
<text top="74" left="51" width="31" height="9" font="0">types <a href="">[</a></text>
<text top="74" left="81" width="5" height="9" font="1"><a href="">5</a></text>
<text top="74" left="86" width="205" height="9" font="0">]. These systematic and random variations are</text>
<text top="85" left="51" width="240" height="9" font="0">machine dependent and can be corrected for the most part</text>
<text top="97" left="51" width="85" height="9" font="0">via image denoising <a href="">[</a></text>
<text top="97" left="135" width="5" height="9" font="1"><a href="">6</a></text>
<text top="97" left="140" width="151" height="9" font="0">], bias field inhomogeneity estimation</text>
<text top="108" left="51" width="4" height="9" font="0"><a href="">[</a></text>
<text top="108" left="54" width="5" height="9" font="1"><a href="">7</a></text>
<text top="108" left="59" width="131" height="9" font="0">], and intensity standardization <a href="">[</a></text>
<text top="108" left="190" width="5" height="9" font="1"><a href="">8</a></text>
<text top="108" left="195" width="6" height="9" font="0"><a href="">].</a></text>
<text top="119" left="66" width="225" height="9" font="0">In this paper we investigated the reliability of our</text>
<text top="131" left="51" width="240" height="9" font="0">DEF metric through analysis of cross-sectional (i.e., one</text>
<text top="142" left="51" width="240" height="9" font="0">timepoint) scan/repeat scan and scan/rescan images from</text>
<text top="153" left="51" width="240" height="9" font="0">two multicentric studies. First, we took advantage of the fact</text>
<text top="165" left="51" width="240" height="9" font="0">that subjects in the Alzheimer’s Disease Neuroimaging Initia-</text>
<text top="176" left="51" width="240" height="9" font="0">tive (ADNI) study received two within-session T1-weighted</text>
<text top="188" left="51" width="240" height="9" font="0">scans at their baseline visit to test for scan/repeat scan</text>
<text top="199" left="51" width="240" height="9" font="0">analysis. Further, we employed data on three participants in</text>
<text top="210" left="51" width="240" height="9" font="0">the Pilot European ADNI that had been scanned at seven</text>
<text top="222" left="51" width="8" height="9" font="0">di</text>
<text top="219" left="59" width="6" height="13" font="2">ﬀ</text>
<text top="222" left="64" width="227" height="9" font="0">erent sites in a short timeframe to test for Scan/Rescan</text>
<text top="233" left="51" width="240" height="9" font="0">reliability. We report minimum clinical trial sample size</text>
<text top="244" left="51" width="90" height="9" font="0">increases at various di</text>
<text top="242" left="141" width="6" height="13" font="2">ﬀ</text>
<text top="244" left="147" width="144" height="9" font="0">erent levels based on the calculated</text>
<text top="256" left="51" width="80" height="9" font="0">detection threshold.</text>
<text top="267" left="66" width="225" height="9" font="0">Reliability analysis is an important, necessary, and often</text>
<text top="279" left="51" width="240" height="9" font="0">overlooked step between bench and bedside in the research</text>
<text top="290" left="51" width="83" height="9" font="0">and clinical contexts.</text>
<text top="316" left="51" width="128" height="11" font="3"><b>2. Materials and Methods</b></text>
<text top="338" left="51" width="240" height="9" font="4"><i>2.1. Ethics. </i>Institutional review boards of all participating</text>
<text top="349" left="51" width="240" height="9" font="0">institutions approved the procedures for this study. Written</text>
<text top="360" left="51" width="240" height="9" font="0">informed consent was obtained from all participants or sur-</text>
<text top="372" left="51" width="157" height="9" font="0">rogates. More information about ADNI</text>
<text top="370" left="208" width="3" height="7" font="5">1</text>
<text top="372" left="214" width="77" height="9" font="0">and Pilot European</text>
<text top="383" left="51" width="232" height="9" font="0">ADNI investigators are provided in the Acknowledgments.</text>
<text top="409" left="51" width="214" height="9" font="4"><i>2.2. Subjects. </i>In this study we used data from three di</text>
<text top="406" left="265" width="6" height="13" font="2">ﬀ</text>
<text top="409" left="271" width="20" height="9" font="0">erent</text>
<text top="420" left="51" width="204" height="9" font="0">studies, totaling 1051 subjects from over 60 centers.</text>
<text top="440" left="68" width="223" height="9" font="0">(i) The first was the <i>Mapping group</i>, consisting of</text>
<text top="451" left="81" width="210" height="9" font="0">145 young control subjects from the International</text>
<text top="462" left="81" width="168" height="9" font="0">Consortium for Brain Mapping database <a href="">[</a></text>
<text top="462" left="249" width="5" height="9" font="1"><a href="">9</a></text>
<text top="462" left="253" width="6" height="9" font="0">].</text>
<text top="478" left="65" width="226" height="9" font="0">(ii) The second was the <i>Classification group</i>, which con-</text>
<text top="489" left="81" width="210" height="9" font="0">sisted in 70 probable AD and 69 CTRL subjects from</text>
<text top="501" left="81" width="101" height="9" font="0">the LENITEM database <a href="">[</a></text>
<text top="501" left="181" width="10" height="9" font="1"><a href="">10</a></text>
<text top="501" left="191" width="100" height="9" font="0"><a href="">]. </a>We required those first</text>
<text top="512" left="81" width="199" height="9" font="0">two groups to build our high-dimensional metric;</text>
<text top="528" left="62" width="229" height="9" font="0">(iii) The third was the <i>Scan/Repeat Test Group</i>, which</text>
<text top="539" left="81" width="210" height="9" font="0">consisted in 1518 baseline MRIs (scan + same-session</text>
<text top="550" left="81" width="210" height="9" font="0">repeat scans) from 759 CTRL, MCI, and probable</text>
<text top="562" left="81" width="210" height="9" font="0">AD subjects participating in ADNI, acquired on more</text>
<text top="573" left="81" width="39" height="9" font="0">than 50 di</text>
<text top="571" left="120" width="6" height="13" font="2">ﬀ</text>
<text top="573" left="126" width="165" height="9" font="0">erent 1.5T scanners using a similar 3D T1-</text>
<text top="584" left="81" width="124" height="9" font="0">weighted MP-RAGE protocol <a href="">[</a></text>
<text top="584" left="204" width="10" height="9" font="1"><a href="">11</a></text>
<text top="584" left="214" width="77" height="9" font="0"><a href="">]</a>. Inclusion criteria</text>
<text top="596" left="81" width="138" height="9" font="0">to the ADNI study were as follows.</text>
<text top="618" left="88" width="124" height="9" font="0">(a) CTRL are MMSE scores <a href="">[</a></text>
<text top="618" left="212" width="10" height="9" font="1"><a href="">12</a></text>
<text top="618" left="221" width="69" height="9" font="0">] between 24–30</text>
<text top="629" left="103" width="88" height="9" font="0">(inclusive), a CDR <a href="">[</a></text>
<text top="629" left="190" width="10" height="9" font="1"><a href="">13</a></text>
<text top="629" left="200" width="91" height="9" font="0"><a href="">] </a>of 0, nondepressed,</text>
<text top="640" left="103" width="188" height="9" font="0">non-MCI, and nondemented. The age range of</text>
<text top="652" left="103" width="188" height="9" font="0">normal subjects was roughly matched to that of</text>
<text top="663" left="103" width="109" height="9" font="0">MCI and mild AD subjects.</text>
<text top="677" left="87" width="204" height="9" font="0">(b) MCI subjects are MMSE scores between 24–</text>
<text top="688" left="103" width="188" height="9" font="0">30 (inclusive), a memory complaint, objective</text>
<text top="699" left="103" width="188" height="9" font="0">memory loss measured by education adjusted</text>
<text top="711" left="103" width="188" height="9" font="0">scores on Wechsler Memory Scale Logical</text>
<text top="722" left="103" width="51" height="9" font="0">Memory II <a href="">[</a></text>
<text top="722" left="154" width="10" height="9" font="1"><a href="">14</a></text>
<text top="722" left="163" width="128" height="9" font="0">], a CDR of 0.5, absence of sig-</text>
<text top="733" left="103" width="188" height="9" font="0">nificant levels of impairment in other cognitive</text>
<text top="74" left="360" width="188" height="9" font="0">domains, essentially preserved activities of daily</text>
<text top="85" left="360" width="140" height="9" font="0">living, and an absence of dementia.</text>
<text top="99" left="346" width="203" height="9" font="0">(c) Mild AD is MMSE scores between 20–26</text>
<text top="110" left="360" width="188" height="9" font="0">(inclusive), CDR of 0.5 or 1.0, and meets</text>
<text top="121" left="360" width="188" height="9" font="0">NINCDS/ADRDA criteria for probable AD</text>
<text top="133" left="360" width="4" height="9" font="0"><a href="">[</a></text>
<text top="133" left="364" width="10" height="9" font="1"><a href="">15</a></text>
<text top="133" left="374" width="6" height="9" font="0"><a href="">].</a></text>
<text top="156" left="339" width="210" height="9" font="0">From the complete ADNI dataset of 822 subjects at</text>
<text top="167" left="339" width="210" height="9" font="0">baseline, we selected individuals for the <i>Scan/Repeat</i></text>
<text top="178" left="339" width="210" height="9" font="4"><i>Test Group </i>that had both valid entry images and pro-</text>
<text top="190" left="339" width="210" height="9" font="0">cessed images that passed <i>automated </i>quality control</text>
<text top="201" left="339" width="4" height="9" font="0"><a href="">[</a></text>
<text top="201" left="342" width="10" height="9" font="1"><a href="">16</a></text>
<text top="201" left="352" width="6" height="9" font="0"><a href="">].</a></text>
<text top="216" left="321" width="228" height="9" font="0">(iv) Finally, the fourth was the <i>Scan/Rescan Test Group</i>,</text>
<text top="228" left="339" width="210" height="9" font="0">which was obtained with permission from the multi-</text>
<text top="239" left="339" width="150" height="9" font="0">centric Pilot European ADNI project <a href="">[</a></text>
<text top="239" left="489" width="10" height="9" font="1"><a href="">17</a></text>
<text top="239" left="498" width="51" height="9" font="0">]. It included</text>
<text top="250" left="339" width="210" height="9" font="0">data from three healthy volunteers acting as human</text>
<text top="262" left="339" width="156" height="9" font="0">quality control phantoms for the study.</text>
<text top="287" left="309" width="240" height="9" font="4"><i>2.3. MRI Acquisitions. </i>Subjects in the <i>Mapping group </i>were</text>
<text top="299" left="309" width="240" height="9" font="0">scanned in Montreal, QC, Canada on a Philips Healthcare</text>
<text top="310" left="309" width="240" height="9" font="0">Gyroscan 1.5T scanner (Best, The Netherlands) using a T1-</text>
<text top="321" left="309" width="240" height="9" font="0">weighted fast gradient echo sequence (sagittal acquisition,</text>
<text top="333" left="309" width="12" height="9" font="0">TR</text>
<text top="331" left="325" width="7" height="12" font="6"><i>=</i></text>
<text top="333" left="336" width="40" height="9" font="0">18 ms, TE</text>
<text top="331" left="379" width="7" height="12" font="6"><i>=</i></text>
<text top="333" left="390" width="33" height="9" font="0">10 ms, 1</text>
<text top="331" left="426" width="7" height="12" font="6"><i>×</i></text>
<text top="333" left="435" width="5" height="9" font="0">1</text>
<text top="331" left="443" width="7" height="12" font="6"><i>×</i></text>
<text top="333" left="452" width="23" height="9" font="0">1 mm</text>
<text top="332" left="475" width="3" height="7" font="5">3</text>
<text top="333" left="482" width="67" height="9" font="0">voxels, flip angle</text>
<text top="344" left="309" width="10" height="9" font="0">30</text>
<text top="342" left="318" width="4" height="8" font="7"><i>◦</i></text>
<text top="344" left="322" width="6" height="9" font="0">).</text>
<text top="356" left="324" width="225" height="9" font="0">Subjects in the <i>Classification group </i>were scanned in</text>
<text top="367" left="309" width="240" height="9" font="0">Brescia, Italy on a single Philips Healthcare Gyroscan 1.0T</text>
<text top="378" left="309" width="240" height="9" font="0">scanner (Best, The Netherlands) using a T1-weighted fast</text>
<text top="390" left="309" width="178" height="9" font="0">field echo sequence (sagittal acquisition, TR</text>
<text top="388" left="489" width="6" height="12" font="8">=</text>
<text top="390" left="498" width="40" height="9" font="0">25 ms, TE</text>
<text top="388" left="542" width="7" height="12" font="6"><i>=</i></text>
<text top="401" left="309" width="5" height="9" font="0">6</text>
<text top="399" left="313" width="2" height="13" font="9"><i>.</i></text>
<text top="401" left="316" width="28" height="9" font="0">9 ms, 1</text>
<text top="400" left="345" width="7" height="12" font="6"><i>×</i></text>
<text top="401" left="355" width="5" height="9" font="0">1</text>
<text top="400" left="361" width="7" height="12" font="6"><i>×</i></text>
<text top="401" left="370" width="32" height="9" font="0">1, 3 mm</text>
<text top="400" left="402" width="3" height="7" font="5">3</text>
<text top="401" left="408" width="30" height="9" font="0">voxels).</text>
<text top="412" left="324" width="225" height="9" font="0">Subjects in the <i>Scan/Repeat Test Group </i>were scanned</text>
<text top="424" left="309" width="58" height="9" font="0">on over 50 di</text>
<text top="421" left="367" width="6" height="13" font="2">ﬀ</text>
<text top="424" left="373" width="176" height="9" font="0">erent 1.5T scanners (GE Medical Systems;</text>
<text top="435" left="309" width="240" height="9" font="0">Siemens Healthcare; Philips Healthcare) using a 3D T1-</text>
<text top="446" left="309" width="195" height="9" font="0">weighted MP-RAGE protocol or its equivalent <a href="">[</a></text>
<text top="446" left="503" width="10" height="9" font="1"><a href="">11</a></text>
<text top="446" left="513" width="36" height="9" font="0"><a href="">]. </a>In this</text>
<text top="458" left="309" width="240" height="9" font="0">protocol, within the same scan session, there were two 3D</text>
<text top="469" left="309" width="240" height="9" font="0">T1-weighted images acquired, allowing us to test reliability</text>
<text top="481" left="309" width="240" height="9" font="0">on this scan/repeat pair. The subject was not taken out of the</text>
<text top="492" left="309" width="118" height="9" font="0">scanner between acquisitions.</text>
<text top="503" left="324" width="225" height="9" font="0">Subjects in the <i>Scan/Rescan Test Group </i>were scanned</text>
<text top="515" left="309" width="172" height="9" font="0">within the span of few weeks at seven di</text>
<text top="512" left="480" width="6" height="13" font="2">ﬀ</text>
<text top="515" left="486" width="63" height="9" font="0">erent European</text>
<text top="526" left="309" width="240" height="9" font="0">centers (Sites 1 to 7), using the ADNI study 3D T1-weighted</text>
<text top="537" left="309" width="88" height="9" font="0">MP-RAGE protocol <a href="">[</a></text>
<text top="537" left="396" width="10" height="9" font="1"><a href="">11</a></text>
<text top="537" left="406" width="143" height="9" font="0"><a href="">]</a>. Six centers collected scan/rescan</text>
<text top="549" left="309" width="240" height="9" font="0">sessions, where the subject was taken out of the scanner</text>
<text top="560" left="309" width="240" height="9" font="0">between acquisitions. This allows us to estimate scan/rescan</text>
<text top="572" left="309" width="136" height="9" font="0">reliability on 18 comparison pairs.</text>
<text top="597" left="309" width="240" height="9" font="4"><i>2.4. Initial Image Processing. </i>We processed all MRI volumes</text>
<text top="608" left="309" width="240" height="9" font="0">identically using the MINC image processing toolbox</text>
<text top="620" left="309" width="4" height="9" font="0"><a href="http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage">(</a></text>
<text top="620" left="312" width="233" height="9" font="1"><a href="http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage">http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage</a></text>
<text top="620" left="545" width="4" height="9" font="0"><a href="http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage">)</a></text>
<text top="631" left="309" width="197" height="9" font="0">and local software as follows: (a) noise removal <a href="">[</a></text>
<text top="631" left="505" width="5" height="9" font="1"><a href="">6</a></text>
<text top="631" left="510" width="39" height="9" font="0">]; (b) raw</text>
<text top="643" left="309" width="186" height="9" font="0">scanner intensity inhomogeneity correction <a href="">[</a></text>
<text top="643" left="495" width="5" height="9" font="1"><a href="">7</a></text>
<text top="643" left="499" width="50" height="9" font="0">]; (c) global</text>
<text top="654" left="309" width="158" height="9" font="0">registration (12 degrees of freedom) <a href="">[</a></text>
<text top="654" left="467" width="10" height="9" font="1"><a href="">18</a></text>
<text top="654" left="476" width="73" height="9" font="0">] to the reference</text>
<text top="665" left="309" width="240" height="9" font="0">image space defined by the BrainWeb T1-weighted image</text>
<text top="677" left="309" width="4" height="9" font="0"><a href="">[</a></text>
<text top="677" left="312" width="10" height="9" font="1"><a href="">19</a></text>
<text top="677" left="322" width="227" height="9" font="0"><a href="">] </a>(1-mm resolution, 0% noise, 0% nonuniformity),</text>
<text top="688" left="309" width="240" height="9" font="0">maximizing the mutual information between the two</text>
<text top="699" left="309" width="41" height="9" font="0">volumes <a href="">[</a></text>
<text top="699" left="350" width="10" height="9" font="1"><a href="">20</a></text>
<text top="699" left="360" width="123" height="9" font="0"><a href="">]; </a>(d) resampling to a 1-mm</text>
<text top="698" left="482" width="3" height="7" font="5">3</text>
<text top="699" left="491" width="58" height="9" font="0">isotropic grid;</text>
<text top="711" left="309" width="240" height="9" font="0">(e) linear clamping to (0–100) intensity range; (f) intensity</text>
<text top="722" left="309" width="69" height="9" font="0">standardization <a href="">[</a></text>
<text top="722" left="378" width="5" height="9" font="1"><a href="">8</a></text>
<text top="722" left="382" width="167" height="9" font="0">]; (g) nonlinear registration of individual</text>
<text top="733" left="309" width="240" height="9" font="0">standardized subject images to the BrainWeb reference;</text>
</page>
</pdf2xml>
